» Articles » PMID: 31183385

IL-21 Expands HIV-1-Specific CD8 T Memory Stem Cells to Suppress HIV-1 Replication In Vitro

Overview
Journal J Immunol Res
Publisher Wiley
Date 2019 Jun 12
PMID 31183385
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Due to the existence of viral reservoirs, the rebound of human immunodeficiency virus type 1 (HIV-1) viremia can occur within weeks after discontinuing combined antiretroviral therapy. Immunotherapy could potentially be applied to eradicate reactivated HIV-1 in latently infected CD4 T lymphocytes. Although the existence of HIV-1-specific CD8 T memory stem cells (Ts) is well established, there are currently no reports regarding methods using CD8 Ts to treat HIV-1 infection. In this study, we quantified peripheral blood antigen-specific CD8 Ts and then expanded HIV-1-specific Ts that targeted optimal antigen epitopes (SL9, IL9, and TL9) in the presence of interleukin- (IL-) 21 or IL-15. The suppressive capacity of the expanded CD8 Ts on HIV-1 production was measured by assessing cell-associated viral RNA and performing viral outgrowth assays. We found that the number of unmutated TL9-specific CD8 Ts positively correlated with the abundance of CD4 T cells and that the expression of IFN- was higher in TL9-specific CD8 Ts than that in non-TL9-specific CD8 Ts. Moreover, the antiviral capacities of IL-21-stimulated CD8 Ts exceeded those of conventional CD8 memory T cells and IL-15-stimulated CD8 Ts. Thus, we demonstrated that IL-21 could efficiently expand HIV-1-specific CD8 Ts to suppress HIV-1 replication. Our study provides new insight into the function of IL-21 in the suppression of HIV-1 replication.

Citing Articles

Potential of Interleukin (IL)-12 Group as Antivirals: Severe Viral Disease Prevention and Management.

A Rahman N, Balasubramaniam V, Yap W Int J Mol Sci. 2023; 24(8).

PMID: 37108513 PMC: 10138811. DOI: 10.3390/ijms24087350.


HIV-Related Immune Activation and Inflammation: Current Understanding and Strategies.

Lv T, Cao W, Li T J Immunol Res. 2021; 2021:7316456.

PMID: 34631899 PMC: 8494587. DOI: 10.1155/2021/7316456.


Autophagy-dependent glutaminolysis drives superior IL21 production in HIV-1-specific CD4 T cells.

Loucif H, Dagenais-Lussier X, Avizonis D, Choiniere L, Beji C, Cassin L Autophagy. 2021; 18(6):1256-1273.

PMID: 34612140 PMC: 9225533. DOI: 10.1080/15548627.2021.1972403.


Lipophagy confers a key metabolic advantage that ensures protective CD8A T-cell responses against HIV-1.

Loucif H, Dagenais-Lussier X, Beji C, Cassin L, Jrade H, Tellitchenko R Autophagy. 2021; 17(11):3408-3423.

PMID: 33459125 PMC: 8632342. DOI: 10.1080/15548627.2021.1874134.

References
1.
Goulder P, Brander C, Tang Y, Tremblay C, Colbert R, Addo M . Evolution and transmission of stable CTL escape mutations in HIV infection. Nature. 2001; 412(6844):334-8. DOI: 10.1038/35085576. View

2.
Ozaki K, Spolski R, Feng C, Qi C, Cheng J, Sher A . A critical role for IL-21 in regulating immunoglobulin production. Science. 2002; 298(5598):1630-4. DOI: 10.1126/science.1077002. View

3.
Strain M, Gunthard H, Havlir D, Ignacio C, Smith D, Leigh-Brown A . Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: intrinsic stability predicts lifelong persistence. Proc Natl Acad Sci U S A. 2003; 100(8):4819-24. PMC: 153639. DOI: 10.1073/pnas.0736332100. View

4.
Siliciano J, Kajdas J, Finzi D, Quinn T, Chadwick K, Margolick J . Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med. 2003; 9(6):727-8. DOI: 10.1038/nm880. View

5.
Lu W, Arraes L, Ferreira W, Andrieu J . Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nat Med. 2004; 10(12):1359-65. DOI: 10.1038/nm1147. View